{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Papasavvas E"],"funding":["Wistar Cancer Center Grant","The Robert I. Jacobs Fund of the Philadelphia Foundation","NIAID NIH HHS","Foundation for the National Institutes of Health","NCI NIH HHS","Herbert Kean, M.D., Family Professorship"],"pagination":["808-822"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11575944"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["213(6)"],"pubmed_abstract":["Type I IFNs play a pivotal role in immune response modulation, yet dysregulation is implicated in various disorders. Therefore, it is crucial to develop tools that facilitate the understanding of their mechanism of action and enable the development of more effective anti-IFN therapeutic strategies. In this study, we isolated, cloned, and characterized anti-IFN-α and anti-IFN-β Abs from PBMCs of individuals treated with IFN-α or IFN-β, harboring confirmed neutralizing Abs. Clones AH07856 and AH07857 were identified as neutralizing anti-IFN-α-specific with inhibition against IFN-α2a, -α2b, and -αK subtypes. Clones AH07859 and AH07866 were identified as neutralizing anti-IFN-β1a-specific signaling and able to block lipopolysaccharide or S100 calcium-binding protein A14-induced IFN-β signaling"],"journal":["Journal of immunology (Baltimore, Md. : 1950)"],"pubmed_title":["Cloning and Functional Characterization of Novel Human Neutralizing Anti-IFN-α and Anti-IFN-β Antibodies."],"pmcid":["PMC11575944"],"funding_grant_id":["P30 CA010815","P30 CA10815","UM1 AI164570"],"pubmed_authors":["Papasavvas E","Kostman JR","Lu L","Cassel J","Majumdar S","Tebas P","Oliva I","Muthumani K","Fair M","Montaner LJ","Mounzer K","Bar-Or A"],"additional_accession":[]},"is_claimable":false,"name":"Cloning and Functional Characterization of Novel Human Neutralizing Anti-IFN-α and Anti-IFN-β Antibodies.","description":"Type I IFNs play a pivotal role in immune response modulation, yet dysregulation is implicated in various disorders. Therefore, it is crucial to develop tools that facilitate the understanding of their mechanism of action and enable the development of more effective anti-IFN therapeutic strategies. In this study, we isolated, cloned, and characterized anti-IFN-α and anti-IFN-β Abs from PBMCs of individuals treated with IFN-α or IFN-β, harboring confirmed neutralizing Abs. Clones AH07856 and AH07857 were identified as neutralizing anti-IFN-α-specific with inhibition against IFN-α2a, -α2b, and -αK subtypes. Clones AH07859 and AH07866 were identified as neutralizing anti-IFN-β1a-specific signaling and able to block lipopolysaccharide or S100 calcium-binding protein A14-induced IFN-β signaling","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep","modification":"2026-06-02T21:05:07.276Z","creation":"2025-04-03T23:57:01.962Z"},"accession":"S-EPMC11575944","cross_references":{"pubmed":["39109927"],"doi":["10.4049/jimmunol.2400265"]}}